88 related articles for article (PubMed ID: 23572163)
1. Differentiated thyroid carcinoma: defining new paradigms for postoperative management.
Durante C; Costante G; Filetti S
Endocr Relat Cancer; 2013 Aug; 20(4):R141-54. PubMed ID: 23572163
[TBL] [Abstract][Full Text] [Related]
2. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
3. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
4. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine ablation: when and how.
Ambrosetti MC; Colato C; Dardano A; Monzani F; Ferdeghini M
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):473-81. PubMed ID: 19910900
[TBL] [Abstract][Full Text] [Related]
6. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
Pacini F; Castagna MG
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
9. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.
Eustatia-Rutten CF; Smit JW; Romijn JA; van der Kleij-Corssmit EP; Pereira AM; Stokkel MP; Kievit J
Clin Endocrinol (Oxf); 2004 Jul; 61(1):61-74. PubMed ID: 15212646
[TBL] [Abstract][Full Text] [Related]
12. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.
Schlumberger M; Ricard M; De Pouvourville G; Pacini F
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):641-50. PubMed ID: 17710085
[TBL] [Abstract][Full Text] [Related]
13. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
14. Changing concepts in the management of differentiated thyroid cancer.
Intenzo CM; Jabbour S; Dam HQ; Capuzzi DM
Semin Nucl Med; 2005 Oct; 35(4):257-65. PubMed ID: 16150246
[TBL] [Abstract][Full Text] [Related]
15. [Current diagnostic method, prognosis estimation and therapy of papillary thyroid cancer: recommendations of the medical universities and the National Oncologic Institute of Budapest].
Esik O; Balázs C; Boér A; Csernay L; Földes J; Füzy M; Horváth OP; Julesz J; Kásler M; Laczi F; Leövey A; Lukács G; Németh G; Perner F; Repa I; Szabolcs I; Szentirmay Z; Trón L; Balázs G
Orv Hetil; 2000 Jan; 141(1):5-16. PubMed ID: 10673852
[TBL] [Abstract][Full Text] [Related]
16. [Differentiated thyroid carcinoma--how to improve the long-term results? Twenty-five-year outcomes of 850 patients].
Melliere D; Hindie E; Becquemin JP; Desgranges P; Allaire E; Geachan E
Bull Acad Natl Med; 2006 Jan; 190(1):89-106; discussion 106-9. PubMed ID: 16878448
[TBL] [Abstract][Full Text] [Related]
17. Postoperative management of differentiated thyroid cancer.
Sabet A; Kim M
Otolaryngol Clin North Am; 2010 Apr; 43(2):329-51, viii-ix. PubMed ID: 20510717
[TBL] [Abstract][Full Text] [Related]
18. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
Saengsuda Y
J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
[TBL] [Abstract][Full Text] [Related]
20. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]